ABSTRACT

Introduction
Patients with von Willebrand disease have a high risk of bleeding during the surgical treatment of varicose veins. Endovenous laser ablation (EVLA) of the great saphenous vein (GSV) is a minimally invasive treatment for saphenofemoral junction incompetence. The number of complications and relapse rate of EVLA are lower than in those of conventional surgical treatment.

Case presentation
A patient with great saphenous vein insufficiency, von Willebrand disease and hypofibrinogenemia successfully underwent endovenous laser ablation. Replacement therapy with cryoprecipitate was administered preoperatively and postoperatively. The surgical procedure and postoperative course were unremarkable.

Conclusion
In patients with von Willebrand disease and other coagulation disorders, endovenous laser ablation is a safe and effective treatment. The use of minimally invasive treatment, the adequate correction of haemostasis, and close cooperation between the haematologist, anaesthesiologist and endovascular surgeon reduce the risk of bleeding.

Key words: Von Willebrand disease; varicose veins; surgery; endovenous laser ablation; great saphenous vein.

INTRODUCTION

Von Willebrand disease (vWD) is the most common congenital haemorrhagic syndrome, characterised by a variety of quantitative and/or qualitative abnormalities in von Willebrand factor (vWF). Mutations, deletions and vWF gene polymorphisms cause vWD. The inheritance is usually autosomal dominant, while severe forms are inherited recessively. There are three main subtypes; type 1 refers to a quantitative deficiency of vWF, while vWF and F VIII are qualitatively normal in approximately 80% of cases; type 2 includes qualitative defects, and type 3 is defined as a complete lack of vWF. vWF is a protein that mediates platelet adhesion and aggregation at the site of vascular injury and serves as a carrier for factor VIII, extending its half-life from approximately 2 hours (in the absence of vWF) to 8-12 hours. An abnormality of vWF can manifest as a primary haemostasis disorder with a prevalence of 0.86%
to 1.6% \(^7\)\(^{-10}\). The prevalence is twice as high in women as in men, likely because menorrhagia contributes to a more frequent diagnosis, particularly of milder forms\(^8\). The likelihood of bleeding depends on the vWD subtype and the level of vWF deficiency\(^11\).

In patients with vWD who require surgery or other invasive procedures, it is necessary to adequately maintain haemostasis preoperatively and postoperatively to prevent bleeding\(^12\)\(^{,13}\). Three main therapeutic modalities are used for the treatment of vWD: desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) acetate, plasma derivatives (complex concentrate FVIII/vWF; cryoprecipitate) and antifibrinolytics\(^5\)\(^{-12}\)\(^{-20}\). If bleeding occurs, it is important to determine whether it resulted from surgery or inadequate haemostasis.

Early treatment of great saphenous vein insufficiency (GSV) is recommended\(^21\) in saphenofemoral reflux. Classical surgical techniques and endovascular treatment are applied in CEAP class C primary chronic venous insufficiency (CVI)\(^22\). Clinical relapses were not significantly different between EVLA or endovenous radiofrequency ablation and surgery\(^23\). Endovenous ablation has advantages in decreasing the incidence of pain, haematoma, and wound infection and aint permitting a more rapid return to work\(^21\). Endovenous laser ablation (EVLA) is applied in the treatment of superficial and perforating venous reflux. EVLA is a safe and effective treatment for GSV insufficiency\(^24\)\(^{-27}\). Relapse after EVLA is 3-5%, whereas that in conventional surgery is 20-40% within 5 years\(^26\).

**CASE PRESENTATION**

We investigated a female patient, 44 years of age, with vWD, hypofibrinogenemia and popliteal and thigh varicose veins. Stage C3 GSV insufficiency was determined using preoperative Doppler colour flow mapping (CDS).

In her personal history, the patient had excessive menstruation and postpartum bleeding. After the second birth, accompanied by heavy and delayed postpartum bleeding, the diagnosis of type I von Willebrand disease was established, along with hypofibrinogenemia of unknown origin. She reported no other diseases. There was no information about hereditary diseases or a tendency to haemorrhage among immediate family members.

Slightly prolonged bleeding time, as measured by the Duke method (4 min 30 sec), slightly lower levels of vWF (49.2%) and lower fibrinogen levels (1.706 g/l) were detected preoperatively. The concentrations of coagulation factors, complete blood count and hepatogram were within the normal range. A haematologist and anaesthesiologist were consulted preoperatively because of the patient’s risk of bleeding. Preoperative and postoperative cryoprecipitate replacement therapy was given due to the simultaneous lack of fibrinogen and type I von Willebrand disease. After adequate preoperative preparation, the corrected haemostasis parameters were within the reference range.

The patient underwent EVLA treatment of the GSV using 1470 nm (Biolitec) 6F catheter and CDS monitoring. During the operation, CDS-guided vein catheterisation was performed along with catheter positioning, tumescent infiltration, laser energy administration and postoperative control. Total intravenous anaesthesia was applied with tu-
mescent local anaesthesia and intraoperative monitoring. The operative course was uncomplicated. The patient was mobile 2 h after the intervention.

On the first and second postoperative days, the fibrinogen values were 1.910 g/l, 2.214 g/l and 2.880 g/l. The bleeding time measurements and haematological parameters remained within the normal range.

The patient was discharged from hospital in good general condition with no local complications 48 h after the intervention. She was monitored from postoperative days 7-30. Postoperatively, graduated elastic compression stockings (23-32 mmHg) were applied, and sclerosant foam was injected into the varicose veins (in an outpatient setting) as sclerotherapy for GSV varicose tributaries and reticular veins.

**DISCUSSION**

In patients with vWD, the aim of surgical treatment is to apply sufficiently effective therapy with minimal risk of bleeding. Erik von Willebrand contributed to the discovery and treatment of vWD when he first described the haemorrhagic syndrome in a 5-year-old girl and her family members in 1926. Zimmerman identified the antigen associated with F VIII and called it vWF. The surgical treatment of patients with von Willebrand disease is complex. In our patient, although in its mild form, type 1 von Willebrand disease was further complicated by hypofibrinogenemia of unknown aetiology. The hereditary haemorrhagic diathesis in these patients increases the risk of bleeding during surgical intervention, and follow-up care is more complicated. Through adequate preoperative and postoperative replacement, the coagulation factors were corrected, and the risk of bleeding was minimised. If venous reflux is not treated appropriately, it can lead to disease progression, the development of superficial thrombophlebitis, vein rupture and bleeding, and the occurrence of venous ulcers and skin lesions. The extensive classical surgical ligation and stripping of varicose veins due to GSV insufficiency has a high risk of bleeding associated with a number of intraoperative and postoperative complications compared with endovenous ablation. The application of minimally invasive EVLA or GSV with adequate correction of haemostasis according to the type of vWD minimizes the risk to the patient, with satisfactory healing of CVI. EVLA exceeds traditional surgical treatment for fewer complications, shorter hospitalisation, reduced treatment costs and more rapid return to daily life activities. The patient subjectively feels better, with less postoperative pain, and the aesthetic outcome is more favourable.

**CONCLUSIONS**

In patients with von Willebrand disease and other coagulation disorders, endovenous laser ablation is the method of choice when surgical treatment of the GSV insufficiency is necessary. The use of minimally invasive methods, appropriate prophylaxis, and intraoperative and perioperative monitoring reduces the risk of bleeding. Through adequate cooperation among haematologists, anesthesiologists and endovascular surgeons, laser ablation of the GSV in patients with coagulation disorders can be performed safely and effectively.

**ACKNOWLEDGEMENTS**

This study was partially financed by the Grant No 175007 from Serbian Ministry of Education and by the Grant No 01-404 from the Ministry of Science, Montenegro.

**REFERENCES**


